Home > Rheumatology > EULAR 2022 > TYK2 inhibition: A rising star in lupus therapy?

TYK2 inhibition: A rising star in lupus therapy?

Presented By
Prof. Eric Morand, Monash University, Australia
EULAR 2022
Phase 2, PAISLEY
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial. Depending on the dosage, up to 58.2% of study drug recipients showed a Systemic Lupus Erythematosus Responder Index (SRI) 4 response, significantly more than on placebo. The randomised-controlled phase 2 PAISLEY study (NCT03252587) evaluated the TYK2 inhibitor deucravacitinib as a treatment for active SLE [1]. The primary endpoint was the number of participants who met the response criteria for SRI(4) at week 32. All 363 participants were on stable background medication and lacked severe organ-threatening disease. After randomisation, they were treated in 4 separate groups, receiving either deucravacitinib 3 mg twice daily,  6 mg twice daily, 12 mg once daily, or placebo. Between week 8 and week 20 of the trial, a tapering of corticosteroids to 7.5 mg...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on